AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

Conditions

Diseases of the Cardiovascular System

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

Objectives

Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Ages
45 years and older
Gender
Both

Find out more about who can participate in this trial

Trial with
University of Cincinnati
Start Date
11/27/2018
End Date
01/18/2022

For more information about this study, contact:

Sara Jasak

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Reshma Narula, MD
Assistant Professor of Neurology; Fellowship Director, Vascular Neurology

Sub-Investigators

Last Updated
11/11/2022
Study HIC
#2000024124

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information